Rapid Micro Biosystems

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company. It provides mission critical automation solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus in 2006 and is headquartered in Lowell, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rapid Micro Biosystems surpasses Q1 revenue targets, eyes global expansion

Rapid Micro Biosystems delivered a strong Q1 performance, exceeding revenue guidance and setting new records in consumable sales.
The company's focus on product innovation and customer-centric solutions positions it well for sustained growth and market expansion.
While challenges in revenue targets and margin improvements exist, strategic planning and operational enhancements offer opportunities for future success.

Rapid Micro Biosystems reports strong Q2 growth and cost-saving initiatives

Rapid Micro Biosystems showcased robust revenue growth and margin improvement in Q2 2024, driven by successful customer engagement and product placements.
While challenges like net losses persist, the company's proactive cost management and revenue outlook reaffirmation signal a commitment to financial health.
Opportunities lie in achieving positive cash flow by 2027, sustained revenue growth, and operational efficiency enhancements for long-term success.

Rapid Micro Biosystems achieves record revenue and focuses on growth

Rapid Micro Biosystems reported strong Q3 performance with record revenue and improved gross margins.
The company's commercial strategy and product launches are driving customer engagement and sales growth.
While challenges like achieving positive cash flow exist, opportunities for revenue growth through new modalities are promising.
Strategic planning and operational efficiency will be key in navigating market dynamics and sustaining growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rapid Micro Biosystems, Inc. is a life sciences technology company. It provides automated solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus on December 29, 2006 and is headquartered in Lexington, MA.

LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference.

Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference

Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q3 2024 Results Conference Call November 1, 2024 9:00 AM ET Company Participants Michael Beaulieu - CFA, VP, IR & Corporate Communications Robert Spignesi - President & CEO Sean Wirtjes - CFO Conference Call Participants Brendan Smith - TD Cowen Dan Arias - Stifel Operator Thank you for standing by. My name is Novi, and I will be your conference operator today.

Rapid Micro Biosystems, Inc. (RPID) Q3 2024 Earnings Call Transcript

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.26 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago.

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

LEXINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2024.

Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results

LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024.

Rapid Micro Biosystems to Announce Third Quarter 2024 Financial Results on November 1, 2024

LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York City.

Rapid Micro Biosystems to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

LEXINGTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2024.

Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results

LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024.

Rapid Micro Biosystems to Announce Second Quarter 2024 Financial Results on August 2, 2024

Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Michael Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Robert Spignesi - President and CEO Sean Wirtjes - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Steven Mah - TD Cowen Operator Thank you for standing by. My name is John, and I will be your conference operator for today.

Rapid Micro Biosystems, Inc. (RPID) Q1 2024 Earnings Call Transcript

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.32 per share a year ago.

Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates

Reports first quarter 2024 total revenue of $5.6 million , representing growth of 11% compared to first quarter 2023

Rapid Micro Biosystems Reports First Quarter 2024 Financial Results

LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2024 financial results prior to the market open on Friday, May 3, 2024.

Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024

Company to give technical presentation on its innovative Growth Direct® Rapid Sterility Application Company to give technical presentation on its innovative Growth Direct® Rapid Sterility Application

Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024

LOWELL, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the virtual KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024.

Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum

LOWELL, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that, effective March 4, 2024, the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase 150,000 shares of the Company's Class A common stock (“Common Stock”) and 75,000 restricted stock units (“RSUs”) to a new employee under the Company's 2023 Inducement Plan, as amended (the “2023 Inducement Plan”).

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rapid Micro Biosystems, Inc. (RPID) Q4 2023 Earnings Call Transcript

Reports fourth quarter 2023 total revenue of $6.3 million , representing 45% growth compared to fourth quarter 2022

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

LOWELL, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the following investor conferences:

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences

LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2023 financial results prior to the market open on Friday, March 1, 2024.

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company's fully automated Growth Direct system and delivers time to organism detection in as little as 12 hours and final time-to-result in as little as one to three days

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

Full year 2023 total revenue expected to be between $22.4 million and $22.6 million, representing growth of over 30% compared to the prior year

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue

Companies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale, data integrity and accelerating time to market Companies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale, data integrity and accelerating time to market

Samsung Biologics selects Rapid Micro Biosystems' Growth Direct® platform to automate critical microbiology quality control testing

LOWELL, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference.

Rapid Micro Biosystems to Present at 42nd Annual J.P. Morgan Healthcare Conference

Corcept Therapeutics

Kintara Therapeutics

Milestone Pharmaceuticals Inc

Motus GI Hlds

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

News for Rapid Micro Biosystems Stock (RPID)